Cardiovascular Benefits of Air Purifier in Patients with Stable Coronary Artery Disease: A Randomized Single-blind Crossover Study

Overview

Journal Front Public Health

Specialty Public Health

Date 2023 Jan 26

PMID 36699920

Authors

Zhe Liu

Qin Wang

Na Li

Chunyu Xu

Yunpu Li

Jun Zhou

Liu Liu

Haijing Zhang

Yang Mo

Feng Han

Dongqun Xu

Affiliations

Soon will be listed here.

Abstract

Background: Exposure to PM will accelerate the progression of cardiovascular diseases. Air purifier can reduce the PM exposure and theoretically alleviate the influence of PM on patients with stable coronary artery disease (SCAD). However, few studies of the protective effect showed significant results because the interferent effects of routine medication had not been taken into account. In order to explore the actual effect on patients with SCAD, we conducted a randomized single-blind crossover air purifier intervention trial.

Method: Levels of PM exposure during intervention and cardiovascular indicators (inflammation, coagulation, plaque stability, and blood lipids) after intervention were detected, meanwhile the information of drug use was obtained by questionnaire. The kinds of drug used by more than 20% of the subjects were sorted out. And the influence of these drugs on cardiovascular indicators was summarized through literature review. Based on that, the drug use was included as a variable in linear mixed effects models that used to analyze the associations between PM exposure reduction by air purifier and cardiovascular indicators.

Results: The result revealed that the interpretation contribution rate of drug use was more than that of PM exposure. The level of C-reactive protein significantly decreased by 20.93% (95%CI: 6.56%, 33.10%), 23.44% (95%CI: 2.77%, 39.39%) and 24.11% (95%CI: 4.21%, 39.69%) on lag1, lag01 and lag02 respectively, while the level of high-density lipoprotein cholesterol significantly increased by 5.10% (95%CI: 0.69%, 9.05%), 3.71% (95%CI: 0.92%, 6.60%) and 6.48% (95%CI: 2.58%, 10.24%) respectively on lag0, lag1 and lag01 associated with an interquartile range decrease of 22.51 μg/m in PM exposure.

Conclusion: The study shows positive effects of air purifier on SCAD, and also provides methodological reference for future related research.

References

Koh K, Son J, Ahn J, Choi Y, Jin D, Park G . Non-lipid effects of statin on hypercholesterolemic patients established to have coronary artery disease who remained hypercholesterolemic while eating a step-II diet. Coron Artery Dis. 2001; 12(4):305-11. DOI: 10.1097/00019501-200106000-00006. View

Schieffer B, Bunte C, Witte J, Hoeper K, Boger R, Schwedhelm E . Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol. 2004; 44(2):362-8. DOI: 10.1016/j.jacc.2004.03.065. View

Azar R, Kassab R, Zoghbi A, Aboujaoude S, El-Osta H, Ghorra P . Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J. 2006; 151(2):521.e1-521.e4. DOI: 10.1016/j.ahj.2005.10.021. View

Chu M, Dong W, Chi R, Pan L, Li H, Hu D . [Effects of high-efficiency particulate air purifiers on indoor fine particulate matter and its constituents in a district of Beijing during winter]. Beijing Da Xue Xue Bao Yi Xue Ban. 2018; 50(3):482-487. View

Chen R, Zhao A, Chen H, Zhao Z, Cai J, Wang C . Cardiopulmonary benefits of reducing indoor particles of outdoor origin: a randomized, double-blind crossover trial of air purifiers. J Am Coll Cardiol. 2015; 65(21):2279-87. PMC: 5360574. DOI: 10.1016/j.jacc.2015.03.553. View

Xiao Z, Theroux P . Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol. 2004; 43(11):1982-8. DOI: 10.1016/j.jacc.2003.10.071. View

Tousoulis D, Andreou I, Tentolouris C, Antoniades C, Papageorgiou N, Gounari P . Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. Int J Cardiol. 2009; 145(3):438-43. DOI: 10.1016/j.ijcard.2009.05.051. View

Chuang H, Ho K, Lin L, Chang T, Hong G, Ma C . Long-term indoor air conditioner filtration and cardiovascular health: A randomized crossover intervention study. Environ Int. 2017; 106:91-96. DOI: 10.1016/j.envint.2017.06.008. View

Lopez Santi R, Valeff E, Duymovich C, Mazziotta D, Mijailovsky N, Filippa G . Effects of an angiotensin-converting enzyme inhibitor (ramipril) on inflammatory markers in secondary prevention patients: RAICES Study. Coron Artery Dis. 2005; 16(7):423-9. DOI: 10.1097/00019501-200510000-00002. View

10.

Makris T, Stavroulakis G, Krespi P, Hatzizacharias A, Triposkiadis F, Tsoukala C . Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hypertens. 2000; 13(7):783-8. DOI: 10.1016/s0895-7061(00)00262-4. View

11.

von Fallois J, Faulhaber H . [Nebivolol, a beta blocker of the 3rd generation: modern therapy of arterial hypertension. Results of a multicenter observation study]. Praxis (Bern 1994). 2001; 90(11):435-41. View

12.

Xu H, Wang T, Liu S, Brook R, Feng B, Zhao Q . Extreme Levels of Air Pollution Associated With Changes in Biomarkers of Atherosclerotic Plaque Vulnerability and Thrombogenicity in Healthy Adults. Circ Res. 2019; 124(5):e30-e43. DOI: 10.1161/CIRCRESAHA.118.313948. View

13.

Hua Y, Xue J, Sun F, Zhu L, Xie M . Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPARalpha/gamma and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes. Pharmacology. 2008; 83(1):18-25. DOI: 10.1159/000166183. View

14.

Heitzer T, Rudolph V, Schwedhelm E, Karstens M, Sydow K, Ortak M . Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol. 2006; 26(7):1648-52. DOI: 10.1161/01.ATV.0000225288.74170.dc. View

15.

Herrmann J, Mayer E . A long-term study of the effects of celiprolol on blood pressure and lipid-associated risk factors. Am Heart J. 1988; 116(5 Pt 2):1416-21. DOI: 10.1016/0002-8703(88)90133-0. View

16.

Fujiwara T, Saito S, Osanai T, Kameda K, Abe N, Higuma T . Decreased plasma and cardiac matrix metalloproteinase activities in patients with coronary artery disease and treated with pravastatin. Eur J Pharmacol. 2008; 594(1-3):146-51. DOI: 10.1016/j.ejphar.2008.07.039. View

17.

Li J, Fang C, Wang C, Hui R . Effects of simvastatin on exercise-induced myocardial ischemia and plasma endothelin-1 concentrations in patients with stable angina. Clin Chim Acta. 2005; 354(1-2):205-8. DOI: 10.1016/j.cccn.2004.10.012. View

18.

Ohtsuka T, Hamada M, Hiasa G, Sasaki O, Suzuki M, Hara Y . Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001; 37(2):412-7. DOI: 10.1016/s0735-1097(00)01121-9. View

19.

Cortellaro M, Cofrancesco E, Boschetti C, Cortellaro F, Mancini M, Mariani M . Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in.... Thromb Haemost. 2000; 83(4):549-53. View

20.

Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T . Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol. 2000; 35(3):714-21. DOI: 10.1016/s0735-1097(99)00594-x. View